baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ultragenyx Pharmaceutical Inc/ US90400D1081 /

2024-05-06 10:00:00 PM	Chg. +0.2600	Volume	Bid10:09:50 AM	Ask10:09:50 AM	High	Low
43.0100USD	+0.61%	1.1 mill. Turnover: 35.43 mill.	17.3000Bid Size: 100	68.3800Ask Size: 100	43.1200	41.8100

GlobeNewswire 05-02 Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 04-30 Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity an...

GlobeNewswire 04-30 Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusu...

GlobeNewswire 04-25 Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 04-19 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 04-15 Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatm...

GlobeNewswire 04-15 Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

GlobeNewswire 04-12 Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients w...

GlobeNewswire 04-12 Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual ...

GlobeNewswire 04-03 Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Confer...

GlobeNewswire 03-27 Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire 03-22 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 03-05 Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

GlobeNewswire 02-28 Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

GlobeNewswire 02-27 Ultragenyx to Participate at Investor Conferences in March

GlobeNewswire 02-23 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 02-15 Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

GlobeNewswire 02-08 Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corpo...

GlobeNewswire 02-06 Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Hep...

GlobeNewswire 02-05 Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treat...

GlobeNewswire 01-25 Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Stu...

GlobeNewswire 01-19 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01-08 Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

GlobeNewswire 01-07 Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Upda...

GlobeNewswire 01-04 Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Ad...

Ultragenyx Pharmaceutical Inc/ US90400D1081 /

If you wish to receive reply to your feedback, please provide your email address.